Bioiberica, a global life science company specialising in the research, production and commercialisation of nutraceutical ingredients, will be shining a spotlight on new clinical research behind its native type II collagen, Collavant n2 (40 mg/ day) at Vitafoods Europe (14-16 May, Geneva, Switzerland).
Noteworthy findings from the trial are set to be presented for the first time at the Osteoarthritis Research Society International (OARSI) World Congress on Osteoarthritis, taking place this week on 18 — 21 April.
Visitors to the company’s stand (F142) at Vitafoods Europe will then have the unique opportunity to discuss the remarkable discoveries with Bioiberica’s experts – including results showing that 40 mg/day Collavant n2 significantly alleviates joint discomfort after exercise; underscoring its potential to enhance consumers’ daily lives.
Attendees can speak to the team to uncover how the scientific insights can be translated into appealing supplements for the mobility sphere, and more.
Collavant n2 shows promise in healthy individuals for first time
Bioiberica’s latest clinical trial, conducted in collaboration with the Poal Institute of Rheumatology in Barcelona, Spain, set out to evaluate the efficacy and tolerability of Collavant n2 on the joint function of healthy volunteers experiencing joint discomfort post-intensive exercise.
Over a six-month period, participants took either 40 mg/day of Collavant n2 native (undenatured) type II collagen or a placebo, and several parameters were assessed at intervals of 60, 90, 120 and 180 days using KOOS (Knee Injury and Osteoarthritis Outcome Score).
The outcomes revealed a significant reduction in joint discomfort on day 120 and an improvement in quality of life from day 90 versus baseline in the Collavant n2 group.
In subjects with basal activity-related discomfort (VAS < 4cm), statistically significant improvements versus placebo were detected at day 180 for both joint discomfort and quality of life. Moreover, Collavant n2 consistently supported faster recovery from discomfort after exercise, during the trial – significantly outperforming the placebo group at day 180.
Ingrid Möller – Rheumatologist at Poal Institute of Rheumatology in Barcelona and lead investigator of the trial – commented: “This marks the first exploration of Collavant n2’s effects in healthy individuals, and not just those with joint health conditions. In my view, native type II collagen is a pro-health nutritional solution and this research confirms my belief that it could be beneficial for ‘everyday consumers’ leading active lifestyles or regularly engaged in sports; a demographic that continues to grow.”
Daniel Martínez-Puig, Head of R&D Human and Animal Health at Bioiberica will present the study’s key insights during Vitafoods Europe (14-16 May, Geneva, Switzerland) at the New Ingredients Theatre (F184) on Wednesday 15 May, at 15.30 CET.
Meet Bioiberica at Vitafoods Europe 2024
In addition to its Collavant n2 research, at this year’s exhibition, Bioiberica is excited to share the latest news behind its other flagship branded ingredients for skin health (Dermial), joint and muscle support (Mobilee) and digestive wellness (DAOgest) and how they’re helping to empower the health evolution.
The company will also reveal its contributions to sustainability in the Life Science sector – providing insights about its Environmental, Sustainable & Governance (ESG) framework, dedicated to advancing Bioiberica’s sustainability initiatives, including ambitions to achieve climate neutrality by 2050.
The team will be on hand to share more details about the company’s recent efforts to achieve two new Sustainable Development Goals (SDGs) this year, as part of its ongoing efforts to support One Health - a multisectoral worldwide health strategy that recognises the interactions and interdependencies between human, animal and environmental health.
